### The origin and underlying driving forces of the SARS-CoV-2 outbreak

- 2 Shu-Miaw Chaw<sup>1</sup>¶, Jui-Hung Tai<sup>1,2</sup>, Shi-Lun Chen<sup>3</sup>, Chia-Hung Hsieh<sup>4</sup>, Sui-Yuan Chang<sup>5</sup>,
- 3 Shiou-Hwei Yeh<sup>6</sup>, Wei-Shiung Yang<sup>2</sup>, Pei-Jer Chen<sup>2</sup>, and Hurng-Yi Wang<sup>2,7, ¶\*</sup>
- 5 <sup>1</sup> Biodiversity Research Center, Academia Sinica, Taipei, Taiwan
- 6 <sup>2</sup> Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei,
- 7 Taiwan

1

4

15

- 8 <sup>3</sup> Department of Life Science, National Taiwan Normal University, Taipei, Taiwan
- 9 <sup>4</sup> Department of Forestry and Nature Conservation, Chinese Culture University,
- 10 Taipei, Taiwan
- <sup>5</sup> Department of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan
- 12 <sup>6</sup> Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine,
- 13 National Taiwan University, Taipei, Taiwan
- <sup>7</sup> Institute of Ecology and Evolutionary Biology, National Taiwan University, Taipei, Taiwan
- 16 Corresponding Author
- 17 E-mail: hurngyi@ntu.edu.tw (HYW)
- 18 These authors contributed equally to this work
- 19 **Running Title:** Evolution at the early stage of SARS-CoV-2 spread
- 20 **Keywords:** positive selection, population genetics, coronavirus, mutational bias,
- 22 Abstract

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

The spread of SARS-CoV-2 since December 2019 has become a pandemic and impacted many aspects of human society. Here, we analyzed genetic variation of SARS-CoV-2 and its related coronavirus and found the evidence of intergenomic recombination. After correction for mutational bias, analysis of 137 SARS-CoV-2 genomes as of 2/23/2020 revealed the excess of low frequency mutations on both synonymous and nonsynonymous sites which is consistent with recent origin of the virus. In contrast to adaptive evolution previously reported for SARS-CoV in its brief epidemic in 2003, our analysis of SARS-CoV-2 genomes shows signs of relaxation of selection. The sequence similarity of the spike receptor binding domain between SARS-CoV-2 and a sequence from pangolin is probably due to an ancient intergenomic introgression. Therefore, SARS-CoV-2 might have cryptically circulated within humans for years before being recently noticed. Data from the early outbreak and hospital archives are needed to trace its evolutionary path and reveal critical steps required for effective spreading. Two mutations, 84S in orf8 protein and 251V in orf3 protein, occurred coincidentally with human intervention. The 84S first appeared on 1/5/2020 and reached a plateau around 1/23/2020, the lockdown of Wuhan. 251V emerged on 1/21/2020 and rapidly increased its frequency. Thus, the roles of these mutations on infectivity need to be elucidated. Genetic diversity of SARS-CoV-2 collected from China was two time higher than those derived from the rest of the world. In addition, in network analysis, haplotypes collected from Wuhan city were at interior and have more mutational connections, both of which are consistent with the observation that the outbreak of cov-19 was originated from China.

#### **SUMMARY**

In contrast to adaptive evolution previously reported for SARS-CoV in its brief epidemic, our analysis of SARS-CoV-2 genomes shows signs of relaxation of selection. The sequence similarity of the spike receptor binding domain between SARS-CoV-2 and a sequence from pangolin is probably due to an ancient intergenomic introgression. Therefore, SARS-CoV-2 might have cryptically circulated within humans for years before being recently noticed. Data from the early outbreak and hospital archives are needed to trace its evolutionary path and reveal critical steps required for effective spreading. Two mutations, 84S in orf8 protein and 251V in orf3 protein, occurred coincidentally with human intervention. The 84S first appeared on 1/5/2020 and reached a plateau around 1/23/2020, the lockdown of Wuhan. 251V emerged on 1/21/2020 and rapidly increased its frequency. Thus, the roles of these mutations on infectivity need to be elucidated.

#### INTRODUCTION

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

A newly emerging coronavirus was detected in patients during an outbreak of respiratory illnesses starting in mid-December of 2019 in Wuhan, the capital of Hubei Province, China [1, 2, 3]. Due to the similarity of its symptoms to those induced by the severe acute respiratory syndrome (SARS) and genome organization similarity, the causal virus was named SARS-CoV-2 by the International Committee on Taxonomy of Viruses [4]. As of 3/16/2020, 167,515 cases of SARS-CoV-2 infection have been confirmed in 114 countries, causing 6,606 fatalities. As a result, WHO declared the first pandemic caused by a coronavirus on 3/11/2020 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports). As the virus continues to spread, numerous strains have been isolated and sequenced. On 3/18/2020, more than 500 complete or nearly complete genomes have been sequenced and made publicly available. SARS-CoV-2 is the seventh coronavirus found to infect humans. Among the other six, SARS-CoV and MERS-CoV can cause severe respiratory illness, whereas 229E, HKU1, NL63, and OC43 produce mild symptoms [5]. Current evidence strongly suggests that all human associated coronaviruses originated from other animals, such as bats and rodents [5, 6]. While SARS-CoV-2 shares similar genomic structure with other coronaviruses [7-10], its sequence differs substantially from some of the betacoronaviruses that infect humans, such as SARS-CoV (approximately 76% identity), MERS-CoV (43% identity), and HKU-1 (33% identity), but exhibits 96% similarity to a coronavirus collected in Yunnan Province, China from a bat, Rhinolophus affinis. Therefore, SARS-CoV-2 most likely originated from bats [2, 11]. Several issues concerning the origin, time of virus introduction to humans, evolutionary patterns, and the underlying driving force of the SARS-CoV-2 outbreak remain

to be clarified [12, 13]. Here, we analyzed genetic variation of SARS-CoV-2 and its related coronaviruses. We discuss how mutational bias influences genetic diversity of the virus and attempt to infer forces that shape SARS-CoV-2 evolution.

#### **RESULTS**

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

#### Molecular evolution of SARS-COV-2 and related coronaviruses

The resulting phylogeny reveals that RaTG13 is the closest relative of SARS-COV-2, followed by pangolin\_2019 and pangolin\_2017, then CoVZC45 and CoVZXC21, and other SARS-related sequences as outgroups (S1 Fig). According to general time reversible model, transition occurred more frequent than transversion with C-T and A-G changes account for 45% and 28%, respectively, of all six types of nucleotide changes. We next estimated the strength of selection for each coding region using the dN and dS. While purifying selection tends to remove amino acid-altering mutations, thus reducing dN and dN/dS, positive selection has the opposite effect, increasing dN and dN/dS [14]. Between SARS-CoV-2 and RaTG13, orf8 gene exhibits the highest dN (0.032) followed by spike (0.013) and orf7 (0.011), all above the genome average of 0.007 (Table 1). dS varies greatly among CDSs with the highest of 0.313 in *spike* and the lowest of 0.018 in *envelope* (genome average 0.168). Finally, dN/dS is the highest in *orf8* (0.105) followed by *orf7* (0.061) and *orf3* (0.060), with the genome average of 0.042. Since spike shows both high dS and dN, its protein evolution rate (dN/dS) is only 0.040. Thus, while the coronavirus evolved very rapidly, it has actually been under tremendous selective constraint [13]. Spike protein similarity between SARS-CoV-2 and pangolin\_2019 led to the idea that the receptor binding domain (RBD) within the SARS-CoV-2 spike protein originated from pangolin\_2019 via recombination [15-18]. If that were the case, we would expect the divergence at synonymous sites (dS) to also be reduced in the RBD region. However, while

dN in the RBD region is 0.023, approximately one third of the estimate for the rest of the *spike* gene (0.068), dS in the RBD (0.710) is actually slightly higher than in the rest of the *spike* sequence (0.651). This argues against the recombination scenario. We noticed that the dS of the whole *spike* and the RBD, are 2- and 3-fold, respectively, higher than the genome average. Since synonymous sites are typically less influenced by selection, the increased divergence in dS may reflect an underlying elevated mutation rate.

#### Genetic variation of SARS-CoV-2

We downloaded 137 SARS-CoV-2 genomes available from GISAID as of 2/23/2019. The coding regions were aligned and 223 mutations were identified with 68 synonymous and 115 nonsynonymous changes. The directionality of changes was inferred based on the RaTG13 sequence. Frequency spectra of both synonymous and nonsynonymous changes are skewed. While the former shows excess of both high and low frequency mutations, the latter mainly exhibits an excess of low frequency changes (Fig. 1a). The excess of low frequency mutations is consistent with the recent origin of SARS-CoV-2 [19]. Both population reduction and positive selection can increase high frequency mutations [20, 21]. However, the first scenario is contradicted by the recent origin of the virus. If positive selection has been operating, we would expect an excess of high frequency non-synonymous as well as synonymous changes. Furthermore, the ratio of nonsynonymous to synonymous changes is 2.46 (138/56) among singleton variants, but only 1.42 (17/12) among non-singletons. Both of these observations suggest that the majority of amino acid-altering mutations are selected against, with no positive selection in evidence.

The skew of synonymous variants toward high frequency deserves further discussion, as it relates to the underlying force driving the SARS-CoV-2 outbreak. The puzzle is probably rooted in how high and low frequency mutations are inferred. The results shown in

the Fig. 1a are based on an outgroup comparison. The divergence at synonymous sites between SARS-CoV-2 and RaTG13 is 17%, approximately 3-fold greater than between humans and rhesus macaques [22]. With such high level of divergence, the possibility of multiple substitutions cannot be ignored, especially since substitution in the coronavirus genome is strongly biased toward transitions (see above). Indeed, among all non-singleton mutations listed in Table 2, 62% of the changes are C-T transitions.

To get around the potential problem caused by multiple substitutions, we cross-referenced the course of changes using the SARS-CoV-2 haplotype network (Fig. 2) and phylogeny (S2 Fig). The two analyses yield very different pictures. For example, the highest frequency derived mutation in Table 2 is a C-T synonymous change at 10138 (marked  $\gamma$  in Fig 2 and Table 2). All three sequences from Singapore share the T nucleotide also found in the RaTG13 outgroup. Using the outgroup comparison, the C found in the rest of the human SARS-CoV-2 sequences is a derived mutation. However, the T at this position is restricted to genomes collected from Singapore on 2/4 and 2/6/2020 and not found in earlier samples. It is thus more sensible to infer that this T is a back mutation derived from C rather than an ancestral nucleotide. Another synonymous change at position 24034 occurred twice (C24034T) on different genomic backgrounds (marked  $\kappa$  in Fig 2). Although the outgroup sequence at this position is T, it is more likely that the C at this position is the ancestral nucleotide. We observed a number of such back or repeated mutations. An A-T nonsynonymous change at 29019 (D249H in nucleocapsid protein, marked O in Fig. 2) also occurred twice.

Repeated mutations may be caused by intergenomic recombination. Indeed, the result of four haplotype test suggested that at least two recombination events may have occurred between positions 8782 and 11083 and between 11083 and 28854. We noticed that a sequence isolated on 1/21/2020 from a patient in the United States (EPI\_ISL\_404253)

exhibited Y (C or T) at both positions 8,782 and 28,144. Although, the possibility that two novel mutations might be occurred within this patient cannot be 100% ruled out, the alternative explanation that this patient may have been co-infected by two viral strains seems more plausible.

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

After cross-referencing with the haplotype network and the phylogeny, all mutations listed as high frequency in Table 2 and Fig. 1a were re-assigned to the other side of the frequency spectra. We only see an excess of singleton mutations, consistent with a recent origin of SARS-CoV-2 (Fig. 1b) and suggesting that the virus has mainly evolved under constraint.

Perhaps the most controversial case is the T-C change at position 28814 which alters Leucine (L) to Serine (S) in orf8 protein (L84S). Since both pangolin and RaTG13 have a C at this position (Table 2), Tang et al suggested that 84L is derived from 84S in the human virus [13]. The 84S was not discovered until 1/5/2020, by which time 23 SARS-CoV-2 genomes have been sampled. After the first appearance, its frequency gradually increased, reaching approximately 30% by 1/23/2020, suggesting that 84S may exhibit some advantage over 84L. If genomes carrying 84S were ancestral, it would be a challenge to explain its absence in early samplings. In addition, as mentioned above, C-T transitions are dominant in coronavirus evolution and multiple hits were observed in SARS-CoV-2 (Fig. 2). It is therefore possible that 28814C mutated to T after ancestral SARS-CoV-2 diverged from the common ancestor with RaTG13 and recently changed back to C. Finally, if 84L is indeed a derived haplotype and has rapidly increased in its frequency by positive selection, we would expect haplotypes carrying 84L to have accumulated more derived mutations than haplotypes with 84S. However, after correcting for mutational direction, the two haplotypes exhibited similar mutation frequency spectra (S3 Fig). The alternative hypothesis that 84S is a back mutation from 84L is more plausible.

#### Selection pressure on SARS-CoV-2

In addition to L84S, a G-T transversion at 26114 which caused an amino acid change in orf3 protein (G251V) is also at intermediate frequency (Table 2). 251V was first seen on 1/22/2020 and gradually increased its frequency to 13% by our sampling date (Fig. 3). We note that the emergence of 84S in orf8 and 251V in orf3 are consistent with the lockdown of Wuhan on 1/23/2020. The former first appeared in early January, gradually increased its frequency, and reached a plateau around 1/23/2020. The latter showed up on 1/22/2020 and rapidly increased its frequency within two weeks.

Based on Fig. 3, we divided the sampling course into two epidemic episodes, from the first sampled sequence (12/24/2019) to before the lockdown of Wuhan (1/21/2020) and from 1/22/2020 to the date of the last sequence sampling (2/23/2020). The dN/dS of coding regions within the two episodes were estimated. As roughly 87% of mutations were singletons. Many of these are probably sequencing errors, affecting synonymous and nonsynonymous sites equally and inflating our dN/dS estimates. In addition, since dN/dS is already extremely small in SARS-CoV-2 (Table 1), such inflation would have a large effect on dN/dS estimates. We therefore excluded singletons from dN and dS estimation.

The dN/dS of *orf8* gene in episode I and II and *orf3* gene in episode II show strong signatures of positive selection, consistent with increase of 84S and 251V frequency during these periods, and may suggest a role of adaptation (Table 3). The overall dN/dS within each episode was 5-10 times higher than dN/dS between coronavirus genomes derived from different species (Table 1). The elevated dN/dS of SARS-CoV-2 is either due to its adaptation to human hosts or relaxation of selection. For a recently emerged virus, it is reasonable to expect operation of positive selection at the early stage. In that case, the dN/dS during episode I should be greater than during episode II [23, 24].

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

However, dN/dS was smaller in episode I than in episode II across the majority of the genome, suggesting that elevation of dN/dS is probably mostly due to the relaxation of selection. We further divided episode I into Ia and Ib, according to the appearance of 84S in orf8 protein on 1/6/2020. The genome-wide dN/dS values were 0.27 and 0.23 for episode 1a and 1b, respectively (S1 Table). Therefore, as shown in the frequency spectra, the signature of positive selection is weak at the early stage of the epidemic. The origin of SARS-CoV-2 The estimated mutation rate of SARS-CoV-2 is 2.4x10<sup>-3</sup>/site/year with 95% highest posterior density (HPD) of 1.5-3.3x10<sup>-3</sup>/site/year. The mutation rate at the third codon position is  $2.9 \times 10^{-3}$ /site/year (95% HPD  $1.8 - 4.0 \times 10^{-3}$ /site/year), which is in a good agreement with synonymous mutation rate of SARS-CoV, 1.67–4.67 x 10<sup>-3</sup> /site/year [24]. SARS-CoV-2 is estimated to have originated on 12/11/2019 (95% HPD 11/13/2019–12/23/2019). We have to point out that the TMRCA estimation is strongly influenced by the genome sampling scheme. Since the earliest available genome was sampled on 12/24/2019 almost one month after the outbreak, the real origin of the current outbreak may actually be earlier than our estimation. We estimated genetic variation, including the number of segregating sites, Watterson's estimator of  $\theta$ , and nucleotide diversity ( $\pi$ ) of the SARS-CoV-2. Since both  $\pi$ and  $\theta$  are estimators of 4Nu (N and u are the effective population size and mutation rate, respectively), they should be close to each other at the mutation-drift equilibrium [25]. Because  $\theta$  is strongly influenced by rare mutations which are common during recent population expansion [14], it is a better estimator of genetic diversity for SARS-CoV-2. For example, when all samples are considered,  $\theta$  (13.92 x 10<sup>-4</sup>) is approximately eight times

higher than  $\pi$  (1.81 x 10<sup>-4</sup>, Table 4). Among samples collected from different locations,

sequences from China exhibited higher genetic variation in terms of the number of segregating sites,  $\theta$  and  $\pi$ , than the rest of the world combined, consistent with the observation that the outbreak originated in China, as the source populations are expected to exhibit higher genetic variation than derived populations [25].

The haplotype network also supports this notion (Fig. 2). Usually, ancestral haplotypes have a greater probability of being in the interior, have more mutational connections, and are geographically more widely distributed. The H1 haplotype is at the center of the network and is found in four countries and many places in China. In addition, a large portion of haplotypes is directly connected to H1. Therefore, it is likely that H1 is the ancestral haplotype. As 45% of H1 are found in Wuhan, this location is the most plausible origin of the ongoing pandemic.

### **DISCUSSION**

A close relationship between SARS-CoV-2 and pangolin\_2019 at the amino acid level in the RBD region of the spike protein might be due to recent recombination [15, 16], data contamination, or convergent evolution. Since recent recombination and DNA contamination should affect synonymous and nonsynonymous sites equally, they can be convincingly rejected as great divergence at synonymous sites was observed in spite of similar amino acid sequences between the two genomes. While genotypic convergence may be observed in viruses repeatedly evolving under particular conditions, such as drug resistance and immune escape [26-29], it is otherwise rare. For adaptations that do not involve highly specialized conditions, divergent molecular pathways may develop and genotypic convergence would not be expected [30]. For example, SARS-CoV and SARS-CoV-2 both use the spike protein to bind human ACE2 [2], but five out of six critical amino acids within the RBD are different between these two viruses [17]. Since the SARS-CoV-2

and pangolin\_2019 have diverged at about 47% of synonymous sites and infect different hosts, the idea that they share five out of six critical amino acids within RBD through convergent evolution seems far-fetched.

We therefore hypothesize that, instead of convergent evolution, the similarity of RBD between SARS-CoV-2 and pangolin\_2019 was caused by an ancient inter-genomic recombination. Assuming a synonymous substitution rate of 2.9x10<sup>-3</sup>/site/year, the recombination was estimated to have occurred approximately 40 years ago (95% HPD : 31-69 years; divergence time (t) = divergence (dS)/(substitution rate x 2 x 3), considering dS in RBD is 3-fold of genome average). The amino acids in the RBD region of the two genomes have been maintained by natural selection ever since, while synonymous substitutions have been accumulated. If this is true, SARS-CoV-2 may have circulated cryptically among humans for years before being recently noticed.

The ancient origin of SARS-CoV-2 is supported by its lack of a signature of adaptive evolution as shown by frequency spectra and dN/dS in samples from the recent epidemic. For a recently acquired virus, rapid evolution and a strong signature of positive selection are expected. For example, during its short epidemic in 2002-2003, several rounds of adaptive changes have been documented in SARS-CoV genomes [23, 24]. After adapting to its host, the virus may evolve under purifying or relaxed selection, exactly as we see in SARS-CoV-2. Therefore, it is important to sequence samples from the early outbreak and to examine hospital archives for the trace of SARS-CoV-2 ancestors. This information not only can help us to understand the evolutionary path of this virus but also unravel the critical steps for it to achieve effective spreading in humans.

In addition to the RBD, the SARS-CoV-2 spike protein also contains a small insertion of a polybasic cleavage site which was thought to be unique within the B lineage of

betacoronaviruses [17]. However, a recent analysis of bats collected from Yunnan, China, identified a similar insertion in a sequence, RmYN02, closely related to SARS-CoV-2, providing strong evidence that such seemingly sorcerous site insertions can occur in nature [11]. Both the polybasic cleavage site in RmYN02 and RBD in pangolin\_2019 suggest that, like with SARS-CoV [6], all genetic elements required to form SARS-CoV-2 may have existed in the environment. More importantly, they can be brought together by frequent intergenomic recombination (see Result). Nature never runs out of material to create new pathogens. It is not whether but when and where the next epidemic will occur.

There is a heated debate about the evolutionary forces influencing the trajectory of the L84S mutation in orf8 protein (http://virological.org/t/response-to-on-the-origin-and-continuing-evolution-of-sars-cov-2/418). While Tang et al. considered Serine is the ancestral amino acid [13], we present evidence that it is a back mutation. The majority of sequences in Wuhan were sampled before early January 2020 and most genomes carrying 84S were found outside Wuhan after middle to late January 2020. The discrepancy in time and space impedes the effort to resolve the debate. It would require more sequences from the early stage of the epidemic to settle this issue. Regardless of its ancestral or derived status, we hypothesize that 84S may confer some selective advantage. Unless the sampling scheme is deliberately skewed, it is difficult to explain such dramatic frequency gain of 84S, from 0 to ~30% in two weeks. Oddly, its frequency ceased to increase after 1/23/2020, when Wuhan was locked down. This coincidence prompts us to consider the effect of social distancing on virus transmission. Another line of evidence comes from the frequency increase of 215V in orf3 protein. The 215V first appeared on 1/22/2020 and rapidly increased its frequency within two weeks.

Several studies suggested that the orf8 protein may function in viral replication, modulating endoplasmic reticulum stress, inducing apoptosis, and inhibiting interferon

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

responses in host cells (41-45 [31, 32-35]. During the SARS spread, frequency of several orf8 mutations fluctuated in accordance with different phases of the outbreak, suggesting that orf8 underwent adaptation during the SARS epidemic [24]. It is suggested that 84S may induce structural disorder in the C-terminus of the protein and may generate a novel phosphorylation target for Serine/Threonine kinases of the mammalian hosts [36]. SARS-CoV orf3 protein has been shown to activate NF-κB and the NLRP3 inflammasome and causes necrotic cell death, lysosomal damage, and caspase-1 activation. In addition, orf3 is required for maximal SARS-CoV replication and virulence. All of the above likely contributes to the clinical manifestations of SARS-CoV infection [37-39]. Therefore, these two mutations may have some functional consequences and be worth investigating further. By the time we prepared this manuscript, the 215V frequency ceased to increase. However, a parallel mutation has occurred in a different genomic background, further supporting the idea that this mutation may require further study. **MATERIALS AND METHODS** Data collection 137 complete SARS-CoV-2 genomes were downloaded from the Global Initiative on Sharing Avian Influenza Data (GISAID, https://www.gisaid.org/). Related coronavirus sequences, including those from five related bat sequences (RaTG13, HUK3-1, ZC45, ZXC-21, and GX2013), two pangolins (each from Guangdong (pangolin\_2019) and Guangxi (pangolin\_2017)), were downloaded from GenBank (https://www.ncbi.nlm.nih.gov/nucleotide/). Nucleotide positions and coding sequences (CDSs) of SARS-CoV-2 were anchored to the reference genome NC\_045512. CDS

annotations of other coronaviruses were downloaded from GenBank.

#### Sequence analyses and phylogeny construction

CDSs were aligned based on translated amino acid sequences using MUSCLE v3.8.31 [40], and back-translated to their corresponding DNA sequences using TRANALIGN software from the EMBOSS package (http://emboss.open-bio.org/) [41]. Nucleotide diversity, including number of segregating sites, Watterson's estimator of  $\theta$  [42], and nucleotide diversity  $(\pi)$ [43], was estimated using MEGA-X [44]. MEGA-X was also used for phylogenetic construction. Phylogenetic relationships were constructed using the neighborjoining method based on Kimura's two-parameter model. Number of nonsynonymous changes per nonsynonymous site (dN) and synonymous changes per synonymous site (dS) among genomes were estimated based Li-Wu-Luo's method [45] implemented in MEGA-X and PAML 4 [46]. The RDP file for the haplotype network analyses was generated using DnaSP 6.0 [47] and input into Network 10 (https://www.fluxus-engineering.com/) to construct the haplotype network using the median joining algorithm. Four haplotype test implemented in DnaSp was applied to test for possible recombination event. The mutation rate of SARS-CoV-2 and the time to the most recent common ancestor (TMRCA) of virus isolates were estimated by an established Bayesian MCMC approach implemented in BEAST version 1.10.4 [48]. The sampling dates were incorporated into TMRCA estimation. The analysis was performed using the HKY model of nucleotide substitution assuming an uncorrelated lognormal molecular clock [49]. We linked substitution rates for the first and second codon positions and allowed independent rates in the third codon position. We performed two independent runs with  $3\times10^8$  MCMC steps and the results were combined. Log files were checked using Tracer (http://beast.bgio.ed.ac.uk/Tracer). Effective sample sizes were >300 for all parameters.

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

#### Acknowledgments

347

355

- The authors thank those who contributed to sequence generation and sharing (The
- detail is listed in S2 Table). We also thank Chung-I Wu and Wen-Ya Ko for their
- constructive comments and suggestions. This work was supported by Ministry of Science and
- 351 Technology, National Taiwan University, and National Taiwan University, College of
- 352 Medicine, Taipei, Taiwan to HYW (105-2628-B-002-015-MY3, 107-2321-B-002-004-,
- NTU-109L7806, NSC-131-5), and partially by a grant form Biodiversity Research Center,
- 354 Academia Sinica to SMC.

#### References

- 356 1. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus
- causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020. Epub 2020/02/01.
- 358 doi: 10.1097/CM9.000000000000722. PubMed PMID: 32004165.
- 359 2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated
- 360 with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. Epub 2020/02/06. doi:
- 361 10.1038/s41586-020-2012-7. PubMed PMID: 32015507.
- 362 3. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with
- 363 human respiratory disease in China. Nature. 2020;579(7798):265-9. Epub 2020/02/06. doi:
- 364 10.1038/s41586-020-2008-3. PubMed PMID: 32015508.
- 365 4. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species
- 366 Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-
- 367 CoV-2. Nat Microbiol. 2020. Epub 2020/03/04. doi: 10.1038/s41564-020-0695-z. PubMed PMID:
- 368 32123347.
- 369 5. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and Sources of Endemic Human
- 370 Coronaviruses. Adv Virus Res. 2018;100:163-88. Epub 2018/03/20. doi: 10.1016/bs.aivir.2018.01.001.
- 371 PubMed PMID: 29551135.
- 372 6. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol.
- 373 2019;17(3):181-92. Epub 2018/12/12. doi: 10.1038/s41579-018-0118-9. PubMed PMID: 30531947.
- 374 7. Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new
- coronavirus epidemic: Evidence for virus evolution. J Med Virol. 2020;92(4):455-9. Epub 2020/01/30.
- 376 doi: 10.1002/jmv.25688. PubMed PMID: 31994738.
- 377 8. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of
- the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020;27(3):325-8. Epub
- 379 2020/02/09. doi: 10.1016/j.chom.2020.02.001. PubMed PMID: 32035028.
- 380 9. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of
- 381 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet.
- 382 2020;395(10224):565-74. Epub 2020/02/03. doi: 10.1016/S0140-6736(20)30251-8. PubMed PMID:
- 383 32007145.
- 384 10. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019
- novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting

- 386 Wuhan. Emerg Microbes Infect. 2020;9(1):221-36. Epub 2020/01/29. doi:
- 387 10.1080/22221751.2020.1719902. PubMed PMID: 31987001.
- 388 11. Zhou H, Chen X, Hu T, Li J, Song H, Liu Y, et al. A novel bat coronavirus reveals natural
- insertions at the S1/S2 cleavage site of the Spike protein and a possible recombinant origin of HCoV-
- 390 19. bioRxiv. 2020:2020.03.02.974139. doi: 10.1101/2020.03.02.974139.
- 391 12. Wu C-I, Poo M-m. Moral imperative for the immediate release of 2019-nCoV sequence data.
- National Science Review. 2020. doi: 10.1093/nsr/nwaa030.
- 393 13. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of
- 394 SARS-CoV-2. National Science Review. 2020. doi: 10.1093/nsr/nwaa036.
- 395 14. Li W-H. Molecular evolution. Sunderland, Mass.: Sinauer Associates; 1997. xv, 487 p. p.
- 396 15. Wong MC, Javornik Cregeen SJ, Ajami NJ, Petrosino JF. Evidence of recombination in
- coronaviruses implicating pangolin origins of nCoV-2019. bioRxiv. 2020:2020.02.07.939207. doi:
- 398 10.1101/2020.02.07.939207.
- 399 16. Xiao K, Zhai J, Feng Y, Zhou N, Zhang X, Zou J-J, et al. Isolation and Characterization of 2019-
- 400 nCoV-like Coronavirus from Malayan Pangolins. bioRxiv. 2020:2020.02.17.951335. doi:
- 401 10.1101/2020.02.17.951335.
- 402 17. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2.
- 403 Nature Medicine. 2020. doi: 10.1038/s41591-020-0820-9.
- 404 18. Lam TT-Y, Shum MH-H, Zhu H-C, Tong Y-G, Ni X-B, Liao Y-S, et al. Identification of 2019-nCoV
- related coronaviruses in Malayan pangolins in southern China. bioRxiv. 2020:2020.02.13.945485. doi:
- 406 10.1101/2020.02.13.945485.
- 407 19. Zhang C, Wang M. Origin time and epidemic dynamics of the 2019 novel coronavirus. bioRxiv.
- 408 2020:2020.01.25.919688. doi: 10.1101/2020.01.25.919688.
- 409 20. Fay JC, Wu Cl. Hitchhiking under positive Darwinian selection. Genetics. 2000;155(3):1405-
- 410 13. Epub 2000/07/06. PubMed PMID: 10880498; PubMed Central PMCID: PMCPMC1461156.
- 411 21. Zeng K, Shi S, Wu Cl. Compound tests for the detection of hitchhiking under positive
- 412 selection. Mol Biol Evol. 2007;24(8):1898-908. Epub 2007/06/15. doi: 10.1093/molbev/msm119.
- 413 PubMed PMID: 17557886.
- 414 22. Wang HY, Chien HC, Osada N, Hashimoto K, Sugano S, Gojobori T, et al. Rate of evolution in
- brain-expressed genes in humans and other primates. PLoS Biol. 2007;5(2):e13. Epub 2006/12/30.
- doi: 10.1371/journal.pbio.0050013. PubMed PMID: 17194215; PubMed Central PMCID:
- 417 PMCPMC1717015.
- 418 23. Yeh SH, Wang HY, Tsai CY, Kao CL, Yang JY, Liu HW, et al. Characterization of severe acute
- 419 respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome
- 420 evolution. Proc Natl Acad Sci U S A. 2004;101(8):2542-7. Epub 2004/02/26. doi:
- 421 10.1073/pnas.0307904100. PubMed PMID: 14983045; PubMed Central PMCID: PMCPMC356986.
- 422 24. Chinese SMEC. Molecular evolution of the SARS coronavirus during the course of the SARS
- 423 epidemic in China. Science. 2004;303(5664):1666-9. Epub 2004/01/31. doi:
- 424 10.1126/science.1092002. PubMed PMID: 14752165.
- 425 25. Hahn MW. Molecular population genetics. New York, Sunderland, MA: Oxford University
- 426 Press; Sinauer Associates; 2018. xviii, 334 pages p.
- 427 26. Wang HY, Chien MH, Huang HP, Chang HC, Wu CC, Chen PJ, et al. Distinct hepatitis B virus
- dynamics in the immunotolerant and early immunoclearance phases. J Virol. 2010;84(7):3454-63.
- 429 Epub 2010/01/22. doi: 10.1128/JVI.02164-09. PubMed PMID: 20089644; PubMed Central PMCID:
- 430 PMCPMC2838120.
- 431 27. Xiang D, Shen X, Pu Z, Irwin DM, Liao M, Shen Y. Convergent Evolution of Human-Isolated
- 432 H7N9 Avian Influenza A Viruses. J Infect Dis. 2018;217(11):1699-707. Epub 2018/02/14. doi:
- 433 10.1093/infdis/jiy082. PubMed PMID: 29438519.
- 434 28. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350(10):1023-35. Epub
- 435 2004/03/05. doi: 10.1056/NEJMra025195. PubMed PMID: 14999114.

- 436 29. Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther. 2010;15 Suppl 3:3-
- 437 14. Epub 2010/11/10. doi: 10.3851/IMP1619. PubMed PMID: 21041899.
- 438 30. Wen H, Wang HY, He X, Wu Cl. On the low reproducibility of cancer studies. Natl Sci Rev.
- 439 2018;5(5):619-24. Epub 2019/07/02. doi: 10.1093/nsr/nwy021. PubMed PMID: 31258951; PubMed
- 440 Central PMCID: PMCPMC6599599.
- 441 31. Muth D, Corman VM, Roth H, Binger T, Dijkman R, Gottula LT, et al. Attenuation of
- replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of
- 443 human-to-human transmission. Sci Rep. 2018;8(1):15177. Epub 2018/10/13. doi: 10.1038/s41598-
- 444 018-33487-8. PubMed PMID: 30310104; PubMed Central PMCID: PMCPMC6181990.
- 32. Sung SC, Chao CY, Jeng KS, Yang JY, Lai MMC. The 8ab protein of SARS-CoV is a luminal ER
- membrane-associated protein and induces the activation of ATF6. Virology. 2009;387(2):402-13. doi:
- 447 10.1016/j.virol.2009.02.021. PubMed PMID: WOS:000265663100019.
- 448 33. Wong HH, Fung TS, Fang S, Huang M, Le MT, Liu DX. Accessory proteins 8b and 8ab of severe
- acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating
- 450 ubiquitin-dependent rapid degradation of interferon regulatory factor 3. Virology. 2018;515:165-75.
- 451 Epub 2018/01/03. doi: 10.1016/j.virol.2017.12.028. PubMed PMID: 29294448.
- 452 34. Le TM, Wong HH, Tay FP, Fang S, Keng CT, Tan YJ, et al. Expression, post-translational
- 453 modification and biochemical characterization of proteins encoded by subgenomic mRNA8 of the
- severe acute respiratory syndrome coronavirus. FEBS J. 2007;274(16):4211-22. Epub 2007/07/25.
- 455 doi: 10.1111/j.1742-4658.2007.05947.x. PubMed PMID: 17645546.
- 456 35. Chen C-Y, Ping Y-H, Lee H-C, Chen K-H, Lee Y-M, Chan Y-J, et al. Open Reading Frame 8a of
- the Human Severe Acute Respiratory Syndrome Coronavirus Not Only Promotes Viral Replication but
- 458 Also Induces Apoptosis. The Journal of Infectious Diseases. 2007;196(3):405-15. doi:
- 459 10.1086/519166.
- 460 36. Ceraolo C, Giorgi FM. Genomic variance of the 2019-nCoV coronavirus. Journal of Medical
- 461 Virology. 2020;92(5):522-8. doi: 10.1002/jmv.25700.
- 462 37. Siu KL, Yuen KS, Castano-Rodriguez C, Ye ZW, Yeung ML, Fung SY, et al. Severe acute
- 463 respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting
- 464 TRAF3-dependent ubiquitination of ASC. FASEB J. 2019;33(8):8865-77. Epub 2019/04/30. doi:
- 465 10.1096/fj.201802418R. PubMed PMID: 31034780; PubMed Central PMCID: PMCPMC6662968.
- 466 38. Yue Y, Nabar NR, Shi CS, Kamenyeva O, Xiao X, Hwang IY, et al. SARS-Coronavirus Open
- 467 Reading Frame-3a drives multimodal necrotic cell death. Cell Death Dis. 2018;9(9):904. Epub
- 468 2018/09/07. doi: 10.1038/s41419-018-0917-y. PubMed PMID: 30185776; PubMed Central PMCID:
- 469 PMCPMC6125346.
- 470 39. Castano-Rodriguez C, Honrubia JM, Gutierrez-Alvarez J, DeDiego ML, Nieto-Torres JL,
- 471 Jimenez-Guardeno JM, et al. Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E,
- 3a, and 8a in Replication and Pathogenesis. mBio. 2018;9(3). Epub 2018/05/24. doi:
- 473 10.1128/mBio.02325-17. PubMed PMID: 29789363; PubMed Central PMCID: PMCPMC5964350.
- 474 40. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput.
- 475 Nucleic Acids Res. 2004;32(5):1792-7. Epub 2004/03/23. doi: 10.1093/nar/gkh340. PubMed PMID:
- 476 15034147; PubMed Central PMCID: PMCPMC390337.
- 477 41. Rice P, Longden I, Bleasby A. EMBOSS: the European Molecular Biology Open Software Suite.
- 478 Trends Genet. 2000;16(6):276-7. Epub 2000/05/29. doi: 10.1016/s0168-9525(00)02024-2. PubMed
- 479 PMID: 10827456.
- 480 42. Watterson GA. On the number of segregating sites in genetical models without
- recombination. Theoretical Population Biology. 1975;7(2):256-76. doi:
- 482 <a href="https://doi.org/10.1016/0040-5809(75)90020-9">https://doi.org/10.1016/0040-5809(75)90020-9</a>.
- 483 43. Nei M, Li WH. Mathematical model for studying genetic variation in terms of restriction
- 484 endonucleases. Proc Natl Acad Sci U S A. 1979;76(10):5269-73. Epub 1979/10/01. doi:
- 485 10.1073/pnas.76.10.5269. PubMed PMID: 291943; PubMed Central PMCID: PMCPMC413122.

- 486 44. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics
- 487 Analysis across Computing Platforms. Mol Biol Evol. 2018;35(6):1547-9. Epub 2018/05/04. doi:
- 488 10.1093/molbev/msy096. PubMed PMID: 29722887; PubMed Central PMCID: PMCPMC5967553.
- 489 45. Li WH, Wu CI, Luo CC. A new method for estimating synonymous and nonsynonymous rates
- 490 of nucleotide substitution considering the relative likelihood of nucleotide and codon changes. Mol
- 491 Biol Evol. 1985;2(2):150-74. Epub 1985/03/01. doi: 10.1093/oxfordjournals.molbev.a040343.
- 492 PubMed PMID: 3916709.

- 493 46. Yang Z. PAML 4: phylogenetic analysis by maximum likelihood. Mol Biol Evol.
- 494 2007;24(8):1586-91. Epub 2007/05/08. doi: 10.1093/molbev/msm088. PubMed PMID: 17483113.
- 495 47. Rozas J, Ferrer-Mata A, Sanchez-DelBarrio JC, Guirao-Rico S, Librado P, Ramos-Onsins SE, et
- al. DnaSP 6: DNA Sequence Polymorphism Analysis of Large Data Sets. Mol Biol Evol.
- 497 2017;34(12):3299-302. Epub 2017/10/14. doi: 10.1093/molbev/msx248. PubMed PMID: 29029172.
- 498 48. Suchard MA, Lemey P, Baele G, Ayres DL, Drummond AJ, Rambaut A. Bayesian phylogenetic
- and phylodynamic data integration using BEAST 1.10. Virus Evol. 2018;4(1). doi: UNSP vey016
- 500 10.1093/ve/vey016. PubMed PMID: WOS:000437019000021.
- 501 49. Drummond AJ, Ho SY, Phillips MJ, Rambaut A. Relaxed phylogenetics and dating with
- 502 confidence. PLoS Biol. 2006;4(5):e88. Epub 2006/05/11. doi: 10.1371/journal.pbio.0040088. PubMed
- 503 PMID: 16683862; PubMed Central PMCID: PMCPMC1395354.

Table 1. Pairwise comparison of nonsynonymous (dN; above slash) and synonymous (dS; below slash) divergence between SARS-CoV-2, RaTG13, and Pangolin\_2019 of different coding regions.

507

| Gene                      | Length (aa) | SARS-CoV-2 vs<br>RaTG13 | SARS-CoV-2 vs<br>Pangolin_2019 | RaTG13 vs<br>Pangolin_2019 |
|---------------------------|-------------|-------------------------|--------------------------------|----------------------------|
| All                       | 9555        | 0.007/0.168             | 0.024/0.469                    | 0.025/0.467                |
|                           |             | (0.042)*                | (0.051)                        | (0.054)                    |
| orf1a                     | 4330        | 0.008/0.166             | 0.024/0.472                    | 0.023/0.472                |
|                           |             | (0.048)                 | (0.051)                        | (0.049)                    |
| orf1b                     | 2692        | 0.003/0.126             | 0.008/0.505                    | 0.010/0.515                |
|                           |             | (0.024)                 | (0.016)                        | (0.019)                    |
| spike                     | 1219        | 0.013/0.313             | 0.068/0.651                    | 0.073/0.680                |
|                           |             | (0.040)                 | (0.104)                        | (0.107)                    |
| RBD of spike <sup>A</sup> | 219         | 0.055/0.511             | 0.023/0.710                    | 0.058/0.863                |
|                           |             | (0.107)                 | (0.032)                        | (0.068)                    |
| orf3                      | 274         | 0.009/0.156             | 0.019/0.285                    | 0.019/0.261                |
|                           |             | (0.060)                 | (0.066)                        | (0.072)                    |
| envelope                  | 75          | 0/0.018                 | 0/0.037                        | 0/0.018                    |
|                           |             | (0)                     | (0)                            | (0)                        |
| matrix                    | 221         | 0.004/0.186             | 0.010/0.299                    | 0.006/0.317                |
|                           |             | (0.021)                 | (0.033)                        | (0.019)                    |
| orf6                      | 60          | 0/0.099                 | 0.014/0.220                    | 0.014/0.345                |
|                           |             | (0)                     | (0.062)                        | (0.040)                    |
| orf7                      | 121         | 0.011/0.177             | 0.018/0.275                    | 0.029/0.329                |
|                           |             | (0.061)                 | (0.066)                        | (0.088)                    |
| orf8                      | 121         | 0.032/0.303             | 0.025/0.362                    | 0.017/0.391                |
|                           |             | (0.105)                 | (0.069)                        | (0.042)                    |
| nucleocapsid              | 415         | 0.005/0.124             | 0.011/0.145                    | 0.010/0.125                |

|   |  | (0.042) | (0.076) | (0.080) |  |  |
|---|--|---------|---------|---------|--|--|
| *Numbers in parentheses are dN/dS               |  |         |         |         |  |  |
| A: RBD, Receptor binding domain of <i>spike</i> |  |         |         |         |  |  |

Table 2. List of non-singleton mutations of SARS-CoV-2

|      | Genome position | Gene   | RaTG13 | Pangolin_2<br>017 | Pangolin_2<br>019 | Major<br>allele | Minor<br>allele | amou<br>char |    |         |
|------|-----------------|--------|--------|-------------------|-------------------|-----------------|-----------------|--------------|----|---------|
| Nons | synonymou       | s      |        |                   |                   |                 |                 | I            | II |         |
| A    | 614             | orflab | G      | G                 | G                 | G               | A               | 2            |    | H116Q   |
| В    | 1190            | orf1ab | C      | C                 | C                 | C               | T               | 3            |    | P308S   |
| C    | 5084            | orflab | A      | A                 | A                 | A               | G               | 2            |    | A1606T  |
| D    | 9438            | orf1ab | C      | C                 | C                 | C               | T               | 3            |    | T3058I  |
| E    | 11083           | orf1ab | G      | T                 | G                 | G               | T               | 9            |    | L3606F  |
| F    | 18488           | orf1ab | T      | T                 | T                 | T               | C               | 2            |    | I6074V  |
| G    | 21707           | S      | C      | C                 | N/A               | C               | T               | 5            |    | H48Y    |
| Н    | 22661           | S      | G      | G                 | G                 | G               | T               | 5            |    | V366F   |
| I    | 26144           | orf3   | G      | G                 | G                 | G               | T               | 18           |    | G251V   |
| J    | 27147           | M      | G      | G                 | G                 | G               | C               | 2            |    | I208T   |
| K    | 28077           | orf8   | G      | G                 | G                 | G               | C               | 4            |    | V61L    |
| L    | 28144           | orf8   | C      | C                 | C                 | T               | C               | 99           | 38 | L84S    |
| M    | 28854           | N      | C      | C                 | C                 | C               | T               | 5            |    | S194L   |
| N    | 28878           | N      | G      | G                 | G                 | G               | A               | 6            |    | S202N   |
| O    | 29019           | N      | A      | A                 | A                 | A               | T               | 2            |    | D249H   |
| P    | 29303           | N      | C      | C                 | C                 | C               | T               | 2            |    | K343I   |
| Sync | onymous         |        |        |                   |                   |                 |                 |              |    |         |
| α    | 2662            | orf1ab | C      | T                 | T                 | C               | T               | 3            |    | C2397T  |
| β    | 8782            | orf1ab | T      | T                 | T                 | C               | T               | 100          | 37 | C8517T  |
| γ    | 10138           | orf1ab | T      | T                 | T                 | C               | T               | 134          | 3  | C9873T  |
| δ    | 15324           | orf1ab | C      | C                 | C                 | C               | T               | 2            |    | C15059T |
| €    | 17373           | orf1ab | T      | C                 | T                 | C               | T               | 132          | 5  | C17108T |
| ζ    | 18060           | orf1ab | T      | T                 | A                 | C               | T               | 131          | 6  | C17795T |
| η    | 18603           | orf1ab | T      | T                 | C                 | T               | A               | 2            |    | T18338C |
| θ    | 23569           | S      | A      | C                 | A                 | T               | C               | 2            |    | T2007C  |

| ι | 23605 | S | N/A | N/A | N/A | T | G | 2   |    | T2043G |
|---|-------|---|-----|-----|-----|---|---|-----|----|--------|
| κ | 24034 | S | T   | C   | C   | C | T | 131 | 6  | C2472T |
| λ | 24325 | S | A   | A   | A   | A | G | 2   |    | A2763G |
| μ | 26729 | M | T   | T   | T   | T | C | 4   |    | T207C  |
| ν | 29095 | N | T   | T   | T   | C | T | 125 | 12 | C822T  |

I Number of changes was inferred by outgroup comparison only

II Number of changes was cross-referenced with the haplotype network of SARS-CoV-2, only numbers which are different from method I are shown.

E: envelope; M: matrix; N: nucleocapsid; S: spike

Table 3. List of dN, dS, and dN/dS in coding regions of SARS-CoV-2 within two episodes

| Gene          | _                      | I (N=57)             | _                     | II (N=79)            |                       | de I+II              |
|---------------|------------------------|----------------------|-----------------------|----------------------|-----------------------|----------------------|
|               | (2019/12/24-2020/1/21) |                      | (2020/1/22-2020/2/23) |                      | (2019/12/24-2020/2/23 |                      |
|               | dN X 10 <sup>4</sup>   | dS X 10 <sup>4</sup> | dN X 10 <sup>4</sup>  | dS X 10 <sup>4</sup> | dN X 10 <sup>4</sup>  | dS X 10 <sup>4</sup> |
|               | dN/dS                  |                      | dN                    | /dS                  | dN                    | /dS                  |
| All           | 0.35                   | 1.48                 | 0.79                  | 1.69                 | 0.62                  | 1.61                 |
|               | 0.                     | 24                   | 0.                    | 47                   | 0.                    | 38                   |
| orfla         | 0.10                   | 1.27                 | 0.38                  | 1.81                 | 0.27                  | 1.58                 |
|               | 0.                     | 08                   | 0.                    | 21                   | 0.                    | 17                   |
| orf1b         | 0.06                   | 0.72                 | 0.08                  | 1.46                 | 0.07                  | 1.16                 |
|               | 0.                     | 08                   | 0.                    | 0.05                 |                       | 06                   |
| spike         | 0.24                   | 2.29                 | 0.66                  | 1.68                 | 0.49                  | 1.93                 |
|               | 0.1                    |                      | 0.39                  |                      | 0.25                  |                      |
| orf3          | 0.00                   | 0.00                 | 5.46                  | (1.69)*              | 3.53                  | (1.61)*              |
|               | 0.00                   |                      | 3.22                  |                      | 2.19                  |                      |
| envelope      | 0.00                   | 0.00                 | 0.00                  | 0.00                 | 0.00                  | 0.00                 |
|               | 0.00                   |                      | 0.00                  |                      | 0.                    | 00                   |
| matrix        | 0.00                   | 4.18                 | 1.00                  | 3.07                 | 0.58                  | 3.51                 |
|               | 0.00                   |                      | 0.32                  |                      | 0.17                  |                      |
| orf6          | 0.00                   | 0.00                 | 0.00                  | 0.00                 | 0.00                  | 0.00                 |
|               | 0.00                   |                      | 0.00                  |                      | 0.00                  |                      |
| orf7          | 0.00                   | 0.00                 | 0.00                  | 0.00                 | 0.00                  | 0.00                 |
|               | 0.                     | 00                   | 0.00                  |                      | 0.00                  |                      |
| orf8          | 16.78                  | (1.48)*              | 16.35                 | (1.69)*              | 16.42                 | (1.61)*              |
|               | 11.32                  |                      | 9.65                  |                      | 10.21                 |                      |
| nucleocapsid  | 1.17                   | 6.94                 | 3.02                  | 4.04                 | 2.28                  | 5.34                 |
|               | 0.17                   |                      | 0.                    | 0.75                 |                       | 43                   |
| *There were n | o synonymou            | ıs mutations ir      | this region.          | The genome-          | wide dS value         | e was used           |

here.

515

516

One sequence from South Korea (EPI\_ISL\_411929) did not have sampling date which was not included in this analysis.

# Table 4 Nucleotide diversity of SARS-CoV-2 across geographic regions

| Sample origin        |                                 | Sample size | S   | θ x 10 <sup>-4</sup> | π x 10 <sup>-4</sup> |
|----------------------|---------------------------------|-------------|-----|----------------------|----------------------|
| Total                |                                 | 137         | 223 | 13.92                | 1.81                 |
| China                |                                 | 64          | 157 | 11.38                | 2.10                 |
|                      | Wuhan                           | 24          | 41  | 2.76                 | 1.16                 |
|                      | Rest of China                   | 40          | 119 | 9.59                 | 2.62                 |
| Rest of the<br>World |                                 | 73          | 81  | 5.71                 | 1.52                 |
|                      | USA                             | 17          | 28  | 2.84                 | 1.71                 |
|                      | Rest of the World excluding USA | 56          | 62  | 4.63                 | 1.43                 |

S: Number of segregating sites.

θ: Nucleotide diversity based on Watterson (29)

 $<sup>\</sup>pi$ : Nucleotide diversity based on Nei and Li (30)

Figure Legend

Figure 1. Frequency spectra of SARS-CoV-2.

(A) The direction of changes was based on outgroup comparison with RaTG13. (B) The direction of changes was cross-referenced with the haplotype network showing in Fig. 2

Fig. 2 Haplotype network of SARS-CoV-2.

Mutation types and numbers are given along the branch. Mutations that are involved in different evolutionary pathways or occurred more than once are enclosed. Also see Table 2 for comparison. Six genomes, EPI\_ISL\_ 408511, 408512, 410480, 408483, 407079, 407079, were excluded from this analysis because they contain too many 'N' in the sequences.

Fig. 3 Mutation frequency of 84S is in orf8 and 215V is in orf3.

The dashed line indicates the date of the Wuhan, China, lockdown.

# Appendix Table.

532

533

534

# Appendix Table 1. List of dN, dS, and dN/dS in coding regions of SARS-CoV-2 within

## episode Ia and Ib

| Gene     | Episode Ia (N=       | -23)                 | Episode Ib (N=34)    |                      |  |
|----------|----------------------|----------------------|----------------------|----------------------|--|
|          | (2019/12/24-20       | )20/1/5)             | (2020/1/6-202        | 20/1/23)             |  |
|          | dN X 10 <sup>4</sup> | dS X 10 <sup>4</sup> | dN X 10 <sup>4</sup> | dS X 10 <sup>4</sup> |  |
|          | dN                   | dN/dS                |                      | /dS                  |  |
| All      | 0.04                 | 0.13                 | 0.47                 | 2.08                 |  |
|          | 0.:                  | 27                   | 0.                   | 23                   |  |
| orfla    | 0.00                 | 0.00                 | 0.16                 | 1.58                 |  |
|          | 0.0                  | 00                   | 0.10                 |                      |  |
| orf1b    | 0.00                 | 0.00                 | 0.09                 | 1.16                 |  |
|          | 0.0                  | 00                   | 0.08                 |                      |  |
| spike    | 0.00                 | 0.98                 | 0.39                 | 3.09                 |  |
|          | 0.0                  | 00                   | 0.13                 |                      |  |
| orf3     | 0.00                 | 0.00                 | 0.00                 | 0.00                 |  |
|          | 0.0                  | 00                   | 0.00                 |                      |  |
| envelope | 0.00                 | 0.00                 | 0.00                 | 0.00                 |  |
|          | 0.0                  | 00                   | 0.00                 |                      |  |
| matrix   | 0.00                 | 0.00                 | 0.00                 | 0.00                 |  |
|          | 0.                   | 00                   | 0.00                 |                      |  |
| orf6     | 0.00                 | 0.00                 | 0.00                 | 0.00                 |  |
|          | 0.0                  | 00                   | 0.00                 |                      |  |
| orf7     | 0.00                 | 0.00                 | 0.00                 | 0.00                 |  |
|          | 0.0                  | 00                   | 0.00                 |                      |  |
| orf8     | 0.00                 | 0.00                 | 21.31                | (2.08)*              |  |
|          | 0.0                  | 00                   | 10                   | .23                  |  |

| nucleocapsid | 0.82 | 0.13 | 1.43 | 10.92 |
|--------------|------|------|------|-------|
|              | 6    | 35   | 0.   | 13    |

Appendix Figures.

shown in Fig. 2

Appendix Figure 1. The neighbor-joining tree of SARS-CoV-2 related coronaviruses constructed by concatenating coding sequences based on the Kimura 2-parameter model implemented in MEGA-X.

Appendix Figure 2. Unrooted neighbor-joining tree of SARS-CoV-2 constructed by concatenating coding sequences based on the Kimura 2-parameter model implemented in MEGA-X. Non-singleton changes are shown along the branches.

The location of each sequence is given (above the slash) followed by its sampling date (below the slash). For multiple sequences sampled on the same date from the same location, the index, a, b, c, d, and etc. is given. Details are listed in Supplemental File 2.

Appendix Figure 3. Frequency spectra of SARS-CoV-2 carrying 84L (n=98) (A) and 84S (n=39) (B) in orf8. The direction of changes was cross-referenced with the haplotype network




Figure 1. Frequency spectra of SARS-CoV-2.

- (A) The direction of changes was based on outgroup comparison with RaTG13.
- (B) The direction of changes was cross-referenced with the haplotype network showing in Fig. 2




Figure 1. Frequency spectra of SARS-CoV-2.

- (A) The direction of changes was based on outgroup comparison with RaTG13.
- (B) The direction of changes was cross-referenced with the haplotype network showing in Fig. 2

A #614 B #1190 #9438 #11083 #27147 #28077 L #28144 M #28854

# Synonomous

| <u> </u> | , y 1 1 O 1 1 1  | oniou  | 3      |
|----------|------------------|--------|--------|
| α        |                  | Orf1ab | C2397T |
| β        | #8782            | Orf1ab | C8517T |
| γ        | #10138           | Orf1ab | C9873T |
| δ        | #15324           | Orf1ab | C15059 |
| 3        | #17373           | Orf1ab | C17108 |
| ζ        | #18060           | Orf1ab | C17795 |
| ή        | #18060<br>#18603 | Orf1ab | C18338 |
| θ        |                  | S      | T2007C |
| ι        | #23605           | S      | T2043G |
| κ        | #24034           | S      | C2472T |
| λ        | #24325           | S      | A27630 |
| μ        | #26729           | M      | T207C  |
| ν        | #29095           | Ν      | C822T  |

Mutation types and numbers are given along the branch. Mutations that are involved in different evolutionary pathways or occurred more than once are enclosed. Also see Table 2 for comparison. Six genomes, EPI\_ISL\_ 408511, 408512, 410480, 408483, 407079, 407079, were excluded from this analysis because they contain too many 'N' in the sequences.






Fig. 3 Mutation frequency of 84S is in orf8 and 215V is in orf3. The dashed line indicates the date of the Wuhan, China, lockdown.






Appendix Figure 1. The neighbor-joining tree of SARS-CoV-2 related coronaviruses constructed by concatenating coding sequences based on the Kimura 2-parameter model implemented in MEGA-X.




Japan/0131.b

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.12.038554; this version posted April 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is Appendix Figure 2. Unrooted for grant for the boundary of the bounda

The location of each sequence is given (above the slash) followed by its sampling date (below the slash). For multiple sequences sampled on the same date from the same location, the index, a, b, c, d, and etc. is given. Details are listed in Supplemental File 2.



Appendix Figure 3. Frequency spectra of SARS-CoV-2 carrying 84L (n=98) (A) and 84S (n=39) (B) in orf8. The direction of changes was cross-referenced with the haplotype network shown in Fig. 2



Appendix Figure 3. Frequency spectra of SARS-CoV-2 carrying 84L (n=98) (A) and 84S (n=39) (B) in orf8. The direction of changes was cross-referenced with the haplotype network shown in Fig. 2